Related Experiment Video
Updated: Jul 8, 2026
05:52
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
Low-grade endometrial stromal sarcoma: a single center's experience with 22 cases
1Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Summary
Low-grade endometrial stromal sarcoma (LGESS) is a slow-growing cancer. Surgery is the main treatment for recurrence, and adjuvant therapies did not improve outcomes for stage I LGESS patients.
Area of Science:
- Gynecologic Oncology
- Pathology
- Surgical Oncology
Background:
- Low-grade endometrial stromal sarcoma (LGESS) is a rare uterine malignancy.
- Understanding its clinical behavior and management is crucial for patient outcomes.
Purpose of the Study:
- To evaluate the clinical behavior and management outcomes of stage I LGESS.
- To identify factors influencing recurrence and survival in LGESS patients.
Main Methods:
- Retrospective review of 22 patients with stage I LGESS diagnosed between 1994 and 2007.
- Analysis of clinicopathologic variables, recurrence patterns, and treatment outcomes.
- Median follow-up of 77 months.
Main Results:
- The median age was 43 years, with abnormal vaginal bleeding as the most common symptom.
- Ten patients experienced recurrence, primarily in the pelvis, followed by the lung and liver.
- Adjuvant therapies (bilateral salpingo-oophorectomy, chemoradiation) did not significantly impact the disease-free interval.
Conclusions:
- LGESS typically follows an indolent clinical course.
- Surgery remains the primary treatment for recurrent disease.
- Adjuvant treatment offers no discernible benefit for stage I LGESS prognosis.
